文献速递肾小球疾病慢性肾脏病

IgA肾病中尿蛋白早期变化与GFR斜率治疗效应的个体参与者荟萃分析

Association of Treatment Effects on Early Change in Urine Protein and Treatment Effects on GFR Slope in IgA Nephropathy: An Individual Participant Meta-analysis.
PubMed 文献 · Am J Kidney Dis · 2021-03-26

该个体患者水平荟萃分析纳入12项随机试验的1037例IgA肾病患者,评估治疗对蛋白尿早期变化与eGFR斜率的影响。贝叶斯混合效应分析显示,蛋白尿治疗效应对3年总斜率和慢性斜率具有高度预测性(中位R²分别为0.88和0.98)。约30%的蛋白尿降低可赋予总斜率和慢性斜率非零治疗获益至少90%的概率。

要点

  • 蛋白尿早期变化可准确预测IgA肾病eGFR总斜率和慢性斜率的治疗效应。
  • 约30%的蛋白尿降低对应eGFR斜率非零获益概率至少90%。
  • 结果支持蛋白尿早期降低作为IgA肾病进展的替代终点。

核心结论

  • 早期蛋白尿降低可作为IgA肾病慢性肾脏病进展研究的替代终点。

研究设计与样本

  • 个体患者水平荟萃分析,纳入12项随机试验共1037例IgA肾病患者。

主要发现

  • 蛋白尿治疗效应对3年总斜率预测中位R²=0.88(95% BCI 0.06-1),对慢性斜率R²=0.98(95% BCI 0.29-1)。
  • 约30%的蛋白尿降低赋予总斜率和慢性斜率非零治疗获益至少90%的概率。
  • 9个月和12个月蛋白尿及2年总斜率结果相似。

临床怎么用

  • 在IgA肾病临床试验中,可采用早期蛋白尿降低作为加速审批的替代终点,并以eGFR斜率验证。

局限性

  • 研究人群限于12项小样本试验,导致贝叶斯可信区间宽。
  • 试验间在设计及干预措施方面存在异质性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: An early change in proteinuria is considered a reasonably likely surrogate end point in immunoglobulin A nephropathy (IgAN) and can be used as a basis for accelerated approval of therapies, with verification in a postmarketing confirmatory trial. Glomerular filtration rate (GFR) slope is a recently validated surrogate end point for chronic kidney disease progression and may be considered as the end point used for verification. We undertook a meta-analysis of clinical trials in IgAN to compare treatment effects on change in proteinuria versus change in estimated GFR (eGFR) slope. STUDY DESIGN: Individual patient-level meta-analysis. SETTING & STUDY POPULATIONS: Individual data of 1,037 patients from 12 randomized trials. SELECTION CRITERIA FOR STUDIES: Randomized trials of IgAN with proteinuria measurements at baseline and 6 (range, 2.5-14) months and at least a further 1 year of follow-up for the clinical outcome. ANALYTICAL APPROACH: For each trial, we estimated the treatment effects on proteinuria and on the eGFR slope, computed as the total slope starting at baseline or the chronic slope starting 3 months after randomization. We used a Bayesian mixed-effects analysis to relate the treatment effects on proteinuria to effects on GFR slope across these studies and developed a prediction model for the treatment effect on the GFR slope based on the effect on proteinuria. RESULTS: Across all studies, treatment effects on proteinuria accurately predicted treatment effects on the total slope at 3 years (median R2 = 0.88; 95% Bayesian credible interval [BCI], 0.06-1) and on the chronic slope (R2 = 0.98; 95% BCI, 0.29-1). For future trials, an observed treatment effect of approximately 30% reduction in proteinuria would confer probabilities of at least 90% for nonzero treatment benefits on the total and chronic slopes of eGFR. We obtained similar results for proteinuria at 9 and 12 months and total slope at 2 years. LIMITATIONS: Study population restricted to 12 trials of small sample size, leading to wide BCIs. There was heterogeneity among trials with respect to study design and interventions. CONCLUSIONS: These results provide new evidence supporting that early reduction in proteinuria can be used as a surrogate end point for studies of chronic kidney disease progression in IgAN.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Inker LA, Heerspink HJL, Tighiouart H, et al. Association of Treatment Effects on Early Change in Urine Protein and Treatment Effects on GFR Slope in IgA Nephropathy: An Individual Participant Meta-analysis. Am J Kidney Dis. 2021. PMID: 33775708. doi:10.1053/j.ajkd.2021.03.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。